+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 5006318
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 139 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Bird Rock Bio
  • Censa Pharmaceuticals
  • CinDome Pharma
  • Theravance Biopharma
  • MORE

‘Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DGp in the 7 Major Markets (MM) ,i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Diabetic Gastroparesis (DGp) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Diabetic Gastroparesis (DGp) - Disease Understanding

The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Symptoms associated with diabetic gastroparesis are early satiety, prolonged fullness, bloating, nausea and vomiting, and abdominal discomfort and pain. These symptoms are vague and nonspecific.

The Diabetic Gastroparesis (DGp) market report gives the thorough understanding of the Diabetic Gastroparesis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Diabetic Gastroparesis in the 7MM.

Diabetic Gastroparesis Epidemiology:

The Diabetic Gastroparesis (DGp) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of Diabetic Gastroparesis, prevalence of Gastroparesis associated with types of Diabetes Mellitus, prevalence of Diabetic Gastroparesis based on gender, prevalence of symptoms associated with Diabetic Gastroparesis) scenario of Diabetic Gastroparesis (DGp) in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017-2030.

According to the publisher, Total prevalent population of Diabetic Gastroparesis in 7 EM was observed to be 12,843,848 cases in 2017.

Diabetic Gastroparesis Drug Chapters:

This segment of the Diabetic Gastroparesis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs along with other potential therapeutic candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment landscape of DGp comprises of very few pharmacotherapies. The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents. The first line of management is focused on optimization of glycemic control known as dietary therapy in addition with the prokinetic therapy in order to improve gastric emptying and gastroparesis symptoms.

Diabetic Gastroparesis Market Outlook:

The Diabetic Gastroparesis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Diabetic Gastroparesis in 7MM was found to be USD 1339.70 Million in 2017, and is expected to increase during the course of the study period (2017-2030). US accounts for the largest market size of Sickle Cell Disease, in comparison to the other 7 Major Markets i.e., United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diabetic Gastroparesis Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Gastroparesis Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Diabetic Gastroparesis Report Key Strengths:

  • 11 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake:

Diabetic Gastroparesis Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Diabetic Gastroparesis market
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Gastroparesis market
  • To understand the future market competition in the Diabetic Gastroparesis market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bird Rock Bio
  • Censa Pharmaceuticals
  • CinDome Pharma
  • Theravance Biopharma
  • MORE
1. Key Insights

2. Executive Summary

3. SWOT Analysis for Diabetic Gastroparesis (DGp)

4. Diabetic Gastroparesis Market Overview at a Glance
4.1. Market Share (%) Distribution of Diabetic Gastroparesis in 2017
4.2. Market Share (%) Distribution of Diabetic Gastroparesis in 2030

5. Disease Background and Overview
5.1. Introduction
5.2. Etiology and risk factors
5.3. Signs and Symptoms
5.4. Pathogenesis of Diabetic Gastroparesis
5.5. Diagnosis
5.5.1. Clinical Scoring System
5.5.2. Differential diagnosis of Diabetic Gastroparesis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Patient Population of Diabetic Gastroparesis

7. Country Wise-Epidemiology of Diabetic Gastroparesis
7.1. The United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Cases of Diabetic Gastroparesis in the United States
7.1.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the United States
7.1.4. Prevalence of Diabetic Gastroparesis based on Gender in the United States
7.1.5. Prevalence of Symptoms associated with DGp in the United States
7.2. EU5
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Cases of Diabetic Gastroparesis in Germany
7.3.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany
7.3.3. Prevalence of Diabetic Gastroparesis based on Gender in Germany
7.3.4. Prevalence of Symptoms associated with DGp in Germany
7.4. France
7.4.1. Total Prevalent Cases of Diabetic Gastroparesis in France
7.4.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France
7.4.3. Prevalence of Diabetic Gastroparesis based on Gender in France
7.4.4. Prevalence of Symptoms associated with DGp in France
7.5. Italy
7.5.1. Total Prevalent Cases of Diabetic Gastroparesis in Italy
7.5.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy
7.5.3. Prevalence of Diabetic Gastroparesis based on Gender in Italy
7.5.4. Prevalence of Symptoms associated with DGp in Italy
7.6. Spain
7.6.1. Total Prevalent Cases of Diabetic Gastroparesis in Spain
7.6.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain
7.6.3. Prevalence of Diabetic Gastroparesis based on Gender in Spain
7.6.4. Prevalence of Symptoms associated with DGp in Spain
7.7. The United Kingdom
7.7.1. Total Prevalent Cases of Diabetic Gastroparesis in the UK
7.7.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK
7.7.3. Prevalence of Diabetic Gastroparesis based on Gender in the UK
7.7.4. Prevalence of Symptoms associated with DGp in the UK
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Cases of Diabetic Gastroparesis in Japan
7.8.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan
7.8.4. Prevalence of Diabetic Gastroparesis based on Gender in Japan
7.8.5. Prevalence of Symptoms associated with DGp in Japan

8. Treatment and Management of Diabetic Gastroparesis
8.1. Consensus guidelines for the clinical management of diabetic gastroparesis
8.2. Algorithm for the management of diabetic gastroparesis
8.3. Patient Journey for Diabetic Gastroparesis

9. Case study for Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Drugs
11.1. Metoclopramide: ANI Pharmaceuticals, Inc
11.1.1. Drug Description
11.1.2. Regulatory Milestones
11.1.3. Other Development Activities
11.1.4. Safety and Efficacy

12. Emerging Therapies
12.1. Relamorelin: Allergan
12.1.1. Product Description
12.1.2. Other Development Activities
12.1.3. Clinical Development
12.1.4. Safety and Efficacy
12.2. Metoclopramide Nasal Spray (Gimoti): Evoke Pharma Inc.
12.2.1. Product Description
12.2.2. Other Development Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.3. Velusetrag: Theravance Biopharma
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.4. Sepiapterin (CNSA-001): Censa Pharmaceuticals
12.4.1. Product Description
12.4.2. Clinical Development
12.5. CIN-102: CinDome Pharma
12.5.1. Product Description
12.5.2. Clinical Development
12.5.3. Safety and Efficacy

13. Other products of interest
13.1. TAK-954: Takeda (Millennium Pharmaceuticals, Inc.)
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.2. TAK-906: Takeda (Millennium Pharmaceuticals, Inc.)
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.3. Nimacimab: Bird Rock Bio
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development

14. Diabetic Gastroparesis: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Diabetic Gastroparesis in 7MM
14.2.1. Market Size of Diabetic Gastroparesis by Therapies

15. Market Outlook by Country
15.1. United States: Market Outlook
15.2. The United States Market Size
15.2.1. Total Market Size of Diabetic Gastroparesis
15.2.2. Market Size of Diabetic Gastroparesis by Therapies

16. EU-5 Countries: Market Outlook
16.1. Germany
16.1.1. Total Market size of Diabetic Gastroparesis
16.1.2. Market Size of Diabetic Gastroparesis by Therapies
16.2. France
16.2.1. Total Market Size of Diabetic Gastroparesis
16.2.2. Market Size of Diabetic Gastroparesis by Therapies
16.3. Italy
16.3.1. Total Market Size of Diabetic Gastroparesis
16.3.2. Market Size of Diabetic Gastroparesis by Therapies
16.4. Spain
16.4.1. Total Market Size of Diabetic Gastroparesis
16.4.2. Market Size of Diabetic Gastroparesis by Therapies
16.5. The United Kingdom
16.5.1. Total Market Size of Diabetic Gastroparesis
16.5.2. Market Size of Diabetic Gastroparesis by Therapies

17. Japan: Market Outlook
17.1. Total Market Size of Diabetic Gastroparesis
17.2. Market Size of Diabetic Gastroparesis by Therapies

18. Market Access and Reimbursement Overview of DGp

19. Market Drivers

20. Market Barriers

21. Appendix
21.1. Bibliography
21.2. Report Methodology

22. Publisher Capabilities

23. Disclaimer

24. About the Publisher
Note: Product cover images may vary from those shown
3 of 3
  • Allergan Evoke Pharma Inc.
  • Theravance Biopharma
  • Censa Pharmaceuticals
  • CinDome Pharma
  • Takeda (Millennium Pharmaceuticals, Inc.)
  • Bird Rock Bio
Note: Product cover images may vary from those shown
Adroll
adroll